IGM Biosciences logo
IGM Biosciences IGMS
report update icon

Quarterly report 2025-Q2
added 05-16-2026

IGM Biosciences Net Debt | IGMS

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt IGM Biosciences

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
18.7 M -72 M -80.1 M -105 M - -21.2 M 3.14 M -432 K - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
18.7 M -105 M -36.6 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
Aclaris Therapeutics Aclaris Therapeutics
ACRS
-17.8 M $ 5.32 0.09 % $ 652 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
-260 M $ 1.05 0.46 % $ 133 M schweizSchweiz
Agenus Agenus
AGEN
-7.52 M $ 7.21 0.7 % $ 214 M usaUSA
Фармсинтез Фармсинтез
LIFE
612 M - - - russiaRussia
Akebia Therapeutics Akebia Therapeutics
AKBA
-133 M $ 0.92 1.64 % $ 237 M usaUSA
Alector Alector
ALEC
-47.4 M $ 1.93 0.81 % $ 199 M usaUSA
Amryt Pharma plc Amryt Pharma plc
AMYT
-107 M - - $ 621 M britainBritain
Aligos Therapeutics Aligos Therapeutics
ALGS
-33.5 M $ 5.05 1.2 % $ 49.9 M usaUSA
Alkermes plc Alkermes plc
ALKS
-319 M $ 46.07 0.09 % $ 7.59 B irlandaIrlanda
Allogene Therapeutics Allogene Therapeutics
ALLO
31.6 M $ 1.69 0.58 % $ 373 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
-604 M $ 239.36 0.46 % $ 31.4 B usaUSA
Altimmune Altimmune
ALT
-9.22 M $ 3.24 0.31 % $ 285 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
-10.9 M $ 1.76 0.53 % $ 94.4 M usaUSA
Evelo Biosciences Evelo Biosciences
EVLO
-2.07 M - -14.46 % $ 27.9 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
457 M $ 23.95 1.31 % $ 1.12 B usaUSA
AnaptysBio AnaptysBio
ANAB
-224 M $ 54.31 0.15 % $ 1.56 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
-31.2 M $ 20.84 0.24 % $ 299 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
8.18 M $ 73.59 2.05 % $ 1.48 B usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
-17 M $ 1.72 0.58 % $ 543 K usaUSA
Allakos Allakos
ALLK
-25 M - - $ 28.6 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
-75.5 M $ 4.82 0.21 % $ 515 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
-206 M $ 15.6 0.25 % $ 427 M israelIsrael
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
150 M $ 4.07 2.21 % $ 147 M usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
-55.8 M $ 25.48 0.54 % $ 286 M usaUSA
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
-46.3 M $ 1.24 0.79 % $ 38.7 M usaUSA
AbbVie AbbVie
ABBV
59.5 B $ 262.51 0.01 % $ 464 B usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
1.89 M $ 10.11 7.1 % $ 127 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
-26.8 M $ 16.96 5.15 % $ 2.28 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-32.7 M $ 1.87 0.53 % $ 498 M britainBritain
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
-63.1 M $ 5.15 1.24 % $ 420 M usaUSA
Axon Enterprise Axon Enterprise
AXON
536 M $ 468.42 5.96 % $ 36.6 B usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
-205 M $ 211.97 3.87 % $ 10.5 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
-19.9 M $ 1.97 0.5 % $ 12.4 M usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
1.44 B $ 68.3 0.1 % $ 13.1 B usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
-625 M $ 3.64 0.68 % $ 252 M britainBritain
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
-2.21 M $ 1.94 1.02 % $ 110 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
-141 M $ 23.1 0.15 % $ 2.28 B usaUSA
Biogen Biogen
BIIB
3.36 B $ 216.01 0.42 % $ 31.6 B usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
-2.04 M $ 2.48 0.79 % $ 6.11 B israelIsrael
AbCellera Biologics AbCellera Biologics
ABCL
14.7 M $ 11.67 2.28 % $ 3.49 B canadaCanada
Benitec Biopharma Benitec Biopharma
BNTC
-179 M $ 11.04 0.9 % $ 514 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
-12.1 M - - $ 231 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
1.56 B $ 3.87 0.8 % $ 848 M britainBritain
Clovis Oncology Clovis Oncology
CLVS
293 M - -7.23 % $ 13 M usaUSA
Chimerix Chimerix
CMRX
-29.9 M - - $ 756 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
-127 M - - $ 401 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
-76.6 M $ 2.49 0.39 % $ 250 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-5.46 M $ 2.24 0.89 % $ 3.69 M israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
-36.1 M $ 17.18 1.7 % $ 1.53 B usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
-14.6 M $ 3.45 0.58 % $ 286 M usaUSA